Modality
Cell Therapy
MOA
CDK4/6i
Target
HER2
Pathway
JAK/STAT
Gastric CaPBC
Development Pipeline
Preclinical
Mar 2019
→ Mar 2031
PreclinicalCurrent
NCT06363576
1,824 pts·PBC
2023-05→2029-01·Terminated
NCT05254526
59 pts·Gastric Ca
2019-03→2031-03·Recruiting
1,883 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-01-222.8y awayInterim· PBC
2031-03-185.0y awayInterim· Gastric Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Interim
2029-01-22 · 2.8y away
PBC
Interim
2031-03-18 · 5.0y away
Gastric Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06363576 | Preclinical | PBC | Terminated | 1824 | LiverFat |
| NCT05254526 | Preclinical | Gastric Ca | Recruiting | 59 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| NBI-3153 | Neurocrine | Approved | Aβ | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |